Launch of Rectify Pharmaceuticals

Country

United States

A new biotech company with plans to target ABC transporters, one of the oldest families of proteins, has been launched with $100 million in Series A financing by US-based Atlas Venture and three other groups. Rectify Pharmaceuticals Inc will develop small molecule drugs aimed at restoring dysfunctional ABC transporters to a normal state. These transporters play an essential role in ferrying organic and inorganic molecules across cellular membranes.